"Ozempic teeth" is not something any document records. The phrase is not in the Ozempic label or any other GLP-1 label, it is not a diagnosis, and no randomised trial has ever measured a tooth in someone taking these drugs. What does exist is a set of side effects the labels count — vomiting, reflux, dry mouth, taste changes — that dentists argue could harm teeth over time, a database of unverified reports, and a small, recent literature. This page counts each.
Everything below was read or run on 20 October 2026: the nine current US labels on DailyMed and openFDA, FDA's adverse-event reports through openFDA, PubMed and ClinicalTrials.gov. The searches are written out so they can be repeated. The page reports; it does not advise. Anyone with a dental concern on one of these drugs has their dentist and prescriber to ask.
The labels: nothing about teeth
The words tooth, teeth, dental, caries, gum, gingival and halitosis do not appear in any of the nine current US labels for the GLP-1 drugs: Ozempic, Wegovy and Rybelsus (semaglutide), Mounjaro and Zepbound (tirzepatide), Saxenda and Victoza (liraglutide), Trulicity (dulaglutide) and Foundayo (orforglipron). Each label was searched in full, including its adverse-reaction tables, its postmarketing section and its patient information. Absence from a label means no dental event was frequent enough in the trials, or reported often enough afterwards, for the FDA to require it. It does not mean the drugs have been shown to be harmless to teeth; no one has looked in a trial.
What the labels do record that could reach the mouth
| Recorded reaction | Drug and trial setting | On drug | Placebo |
|---|---|---|---|
| Vomiting | Wegovy 2.4 mg, weight-management trials | 24% | 6% |
| Vomiting | Zepbound 5 / 10 / 15 mg, weight-management trials | 8 / 11 / 13% | 2% |
| Vomiting | Ozempic 0.5 / 1 mg, diabetes trials | 5.0 / 9.2% | 2.3% |
| Vomiting | Mounjaro 5 / 10 / 15 mg, diabetes trials | 5 / 5 / 9% | 2% |
| Gastro-oesophageal reflux | Wegovy 2.4 mg | 5% | 3% |
| Burping (eructation) | Wegovy 2.4 mg | 7% | under 1% |
| Dry mouth | Saxenda 3 mg | 2.3% | 1.0% |
| Dry mouth or dry throat | Zepbound, pooled | 1% | 0.1% |
| Taste disturbance (dysgeusia) | Wegovy, weight-management trials | 1.7% | 0.5% |
Adverse-reaction sections (6.1) of each label: WEGOVY SPL 2026-06-18; ZEPBOUND 2026-08-28; OZEMPIC 2026-06-01; MOUNJARO 2026-08-27; SAXENDA 2026-02-25. Trial populations differ between rows, so rates are not comparable across drugs.
Two of these matter to the dental argument. Vomiting and reflux bring stomach acid into the mouth, and acid wearing away enamel is the mechanism the dental reviews below cite. Dry mouth reduces saliva, which normally buffers acid and washes the teeth. Neither has been followed through to a dental outcome in GLP-1 users. The reflux and burping figures for every brand are tabled on acid reflux and sulfur burps; nausea, which drives much of the vomiting, is on nausea.
The reports database, counted
FDA's Adverse Event Reporting System (FAERS) collects reports from patients, clinicians and manufacturers. Counts below were run on openFDA, whose data ran to 30 July 2026, for reports naming each drug that list the exact reaction term:
| Reaction term | Semaglutide (73,001 reports) | Tirzepatide (160,663 reports) |
|---|---|---|
| Tooth loss | 42 | 19 |
| Dental caries | 37 | 19 |
| Tooth disorder | 50 | 30 |
| Toothache | 58 | 39 |
| Tooth fracture | 37 | 26 |
| Gingival disorder | 11 | 5 |
| Dry mouth | 434 | 534 |
| Breath odour | 41 | 47 |
Query form: patient.drug.openfda.generic_name:"semaglutide" AND patient.reaction.reactionmeddrapt.exact:"Tooth loss". A report can list several terms.
What these numbers are not. A report means someone told the FDA that a person on the drug had the event; it does not show the drug caused it, the reports are not verified, and there is no denominator of users, so they cannot be turned into a rate. Publicity can also raise the number of reports. Read with that caveat, the counts say one thing clearly: dental terms are rare in the reports — a few dozen each against tens of thousands of reports — while dry mouth is reported roughly ten times as often as any tooth term.
The literature, counted
A PubMed search for (semaglutide[tiab] OR tirzepatide[tiab]) AND (caries[tiab] OR "tooth loss"[tiab] OR "dental erosion"[tiab] OR xerostomia[tiab] OR "dry mouth"[tiab] OR halitosis[tiab] OR "oral health"[tiab]) returned 14 records on 20 October 2026; the same molecules with periodontitis returned 8. The phrases "Ozempic teeth", "Ozempic mouth" and "Ozempic breath" returned none. The records are reviews, laboratory and animal studies, and two kinds of human data:
- The appraisal. Werner and colleagues, in the Journal of Dental Research (October 2026), graded the evidence across dental disciplines and concluded that no prospective study has used any dental outcome as an endpoint in people receiving GLP-1 drugs. They describe the risk of erosion and secondary caries from nausea, vomiting and reflux as "plausible but unquantified", and the reported oral effects — dry mouth, taste change, loss of smell — as coming from pharmacovigilance analyses.
- Reviews of reported cases. Al-Zawawi (2026) lists dry mouth or reduced saliva as the most consistently reported oral effect of semaglutide, often secondary to nausea and eating less, with taste change, oral tingling or numbness, halitosis, frothy saliva and increased caries also reported. Gilligan and colleagues (2026) add that "a direct association with these therapies has not been established" for dental erosion.
- One large records study, pointing the other way. Tu and colleagues (2026) matched 97,993 people with type 2 diabetes on tirzepatide against the same number on other GLP-1 drugs in health records and found lower rates of periodontitis (hazard ratio 0.70), tooth extraction (0.89) and oral infections (0.70) on tirzepatide. It compares two drug classes, not drug against no drug, and as an observational study it cannot show cause.
- Laboratory and animal work consistently reports anti-inflammatory and bone-protective effects on gum and jaw tissue, which is why some dental researchers study these drugs as a possible treatment for gum disease. None of it is clinical evidence about teeth.
The study that will look
ClinicalTrials.gov lists three studies pairing semaglutide or tirzepatide with a dental condition. Only one is about the question this page asks: NCT07720466, "Salivary Function and Dental Changes During GLP-1 Therapy", registered 22 July 2026 by Bilecik Şeyh Edebali University in Türkiye. It plans to enrol about 40 adults before they start semaglutide or tirzepatide for obesity and to measure saliva flow, pH and calcium and tooth wear (on the Basic Erosive Wear Examination index) before treatment and after three months. On 20 October 2026 it was listed as not yet recruiting. Forty people over three months will be a first measurement, not an answer.
Bad breath and dry mouth
No GLP-1 label lists halitosis. The reports database holds 41 semaglutide and 47 tirzepatide reports with breath odour. The explanations offered in the literature are each recorded separately — dry mouth (above), burping, which Wegovy's label puts at 7% against under 1% on placebo, and much lower food intake — but none of these has been measured as a cause of breath odour in GLP-1 users. The sulphur smell some people describe on burping is covered on sulfur burps.
What is not known
- Whether GLP-1 drugs damage teeth at all. No trial or prospective study has measured it.
- How large any effect is, if one exists, or which people would be most exposed — those who vomit often would be the obvious candidates, and that is a hypothesis, not a finding.
- Whether it differs by drug. The one comparison (tirzepatide against other GLP-1 drugs) is observational and found fewer gum problems, not more.
Changes in the face that are also given the drug's name are on Ozempic face, and the full Ozempic label record is on Ozempic side effects. Dental symptoms, and whether they relate to a medicine, are for a dentist and the prescribing clinician to assess.
Sources
- Current US prescribing information, read on DailyMed or openFDA 2026-10-20: WEGOVY (SPL 2026-06-18, v19), OZEMPIC (2026-06-01, v20), MOUNJARO (2026-08-27, v40), ZEPBOUND (2026-08-28, v40), RYBELSUS (2026-01-30, v14), SAXENDA (2026-02-25, v22), VICTOZA (2025-10-14, v31), TRULICITY (2026-06-16, v62), FOUNDAYO (2026-07-29, v10).
- U.S. Food and Drug Administration, FAERS via openFDA drug adverse event API, data last updated 2026-07-30 — queried 2026-10-20.
- Werner N et al. "GLP-1 Receptor Agonists in Dentistry: Promise, Pitfalls, and Evidence Gaps." J Dent Res 2026, PubMed 42873199.
- Al-Zawawi AS. "Oral Adverse Effects of Semaglutide Therapy: A Narrative Review." J Int Soc Prev Community Dent 2026, PubMed 42730115.
- Gilligan G et al. "Adverse Oral and Salivary Effects Associated With Glucagon-Like Peptide-1 Receptor Agonists: Clinical Insights." J Oral Pathol Med 2026, PubMed 42843413.
- Tu CY et al. "Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes." Diabetes Res Clin Pract 2026;242:113573, PubMed 42764072.
- ClinicalTrials.gov, NCT07720466 — read 2026-10-20.